Skip to main content

Saturn Medic

Clinical Subject Page

Diabetic Nephropathy

Diabetic Nephropathy is kidney damage caused by long-standing diabetes mellitus. It is characterized by persistent albuminuria and/or declining kidney function and is a major cause of Chronic Kidney Disease (CKD) and kidney failure

Also called

Diabetic Kidney Disease (DKD)

ICD-10

E10.21 + E11.21

Specialty

Nephrology

Onset

Chronic

Reviewed

August 2026
On This Page

Overview

-Diabetic Nephropathy develops as chronic hyperglycemia causes glomerular and renal vascular injury.

-Important features include:

  • Albuminuria
  • Progressive decline in eGFR
  • Hypertension
  • Progressive Chronic Kidney Disease (CKD)

 

-It may eventually progress to kidney failure.

Etiology & Risk Factors

-Etiology:

Persistent hyperglycemia causes glomerular hyperfiltration, endothelial injury, basement membrane thickening, mesangial expansion, and progressive glomerulosclerosis.

 

 

-Risk Factors:

  • Long duration of diabetes
  • Poor glycemic control
  • Hypertension
  • Smoking
  • Obesity
  • Established diabetic retinopathy

Pathophysiology

Chronic hyperglycemia → glomerular hyperfiltration → endothelial and podocyte injury → glomerular basement membrane thickening → mesangial expansion glomerulosclerosis → albuminuria → declining GFR → Chronic Kidney Disease (CKD) → kidney failure

Clinical Presentation

-Symptoms:

  • Early Diabetic Nephropathy is often asymptomatic.

    Progressive disease may cause:

    • Frothy urine
    • Fatigue
    • Peripheral edema
    • Nocturia
    • Reduced exercise tolerance
    • Symptoms of advanced kidney disease

 

-Signs:

  • Hypertension
  • Peripheral edema
  • Features of diabetic complications
  • Signs of advanced Chronic Kidney Disease (CKD)
Diabetic Nephropathy Overview
Ureteral Stones overview

History Taking

-Ask about:

  • Duration and type of diabetes
  • Glycemic control
  • Previous urine albumin results
  • Blood pressure history
  • Medication adherence
  • Diabetic retinopathy and other microvascular complications
  • Cardiovascular disease
  • Smoking
  • NSAID and nephrotoxic medication use
  • Frothy urine and edema
  • Previous acute kidney injury

Physical Examination

-General Examination

  • Blood pressure
  • Weight and body mass index
  • Peripheral edema
  • Volume status

 

-System-Specific Examination:

  • Fundoscopy for diabetic retinopathy
  • Cardiovascular examination
  • Assessment for other diabetic complications

Investigations

-Biochemistry / Specific Tests

  • Urine albumin-to-creatinine ratio (ACR)

  • Serum creatinine and eGFR

  • Serum potassium

  • Serum bicarbonate

  • Urinalysis

  • HbA1c for glycemic control

Persistent albuminuria should be confirmed because transient elevations can occur with infection, exercise, hyperglycemia, or other acute conditions.

 

-Imaging

Renal ultrasound is not routinely required for typical diabetic kidney disease.

It is useful when another renal pathology is suspected or when there are atypical features.

 

-Special / Confirmatory Tests

Kidney biopsy is not routinely required.

It may be considered when features suggest another kidney disease, such as:

  • Active urinary sediment

  • Rapid unexplained decline in kidney function

  • Sudden heavy proteinuria

  • Absence of typical diabetic microvascular disease

Diagnosis

-Diagnosis of Diabetic Nephropathy  is based on:

  • Diabetes mellitus
  • Persistent albuminuria and/or reduced eGFR
  • Exclusion of alternative kidney disease when clinically indicated

Persistent albuminuria is generally confirmed with repeated testing over time.

Management

1. Definitive Treatment

The main goals are:

  • Optimize glycemic control

  • Control blood pressure

  • Reduce albuminuria

  • Slow progression of Chronic Kidney Disease (CKD)

  • Reduce cardiovascular risk

 

2. Medical Treatment

  • ACE inhibitors or ARBs — particularly for patients with hypertension and albuminuria

  • SGLT2 inhibitors — appropriate patients with type 2 diabetes and Chronic Kidney Disease (CKD), and selected patients with diabetic kidney disease

  • Finerenone — selected patients with type 2 diabetes, CKD, and persistent albuminuria despite optimized renin-angiotensin system blockade

  • Statins for cardiovascular risk reduction

  • GLP-1 receptor agonists may be appropriate for selected patients with type 2 diabetes and cardiovascular or metabolic indications

 

3. Surgical / Procedural Treatment

No routine surgical treatment.

Dialysis or kidney transplantation may be required if kidney failure develops.

 

4. Supportive Management

  • Blood pressure control

  • Glycemic control

  • Sodium restriction

  • Weight management

  • Smoking cessation

  • Avoid NSAIDs and other nephrotoxins

Complications

  • Progressive albuminuria
  • Nephrotic syndrome
  • Hypertension
  • Hyperkalemia
  • Fluid overload
  • Chronic Kidney Disease (CKD)
  • Kidney failure
  • Cardiovascular disease
  • Anemia
  • CKD-mineral and bone disorder

Prognosis

-The prognosis of Diabetic Nephropathy depends mainly on the degree of albuminuria, baseline eGFR, glycemic control, blood pressure control, and cardiovascular disease

Early detection and appropriate kidney-protective therapy can significantly slow progression to kidney failure.

Key Points / Clinical Pearls

  • Diabetic Nephropathy is kidney damage caused by diabetes.
  • It is a major cause of Chronic Kidney Disease (CKD) and kidney failure.
  • Persistent albuminuria is an important early marker.
  • eGFR is essential for assessing kidney function and staging CKD.
  • Long duration of diabetes increases risk.
  • Poor glycemic control and hypertension accelerate progression.
  • Diabetic retinopathy supports the diagnosis but is not required.
  • Urine albumin-to-creatinine ratio (ACR) is a key investigation.
  • Kidney biopsy is not routinely required.
  • ACE inhibitors or ARBs are important in diabetic patients with hypertension and albuminuria.
  • SGLT2 inhibitors provide important kidney-protective effects in appropriate patients.
  • Finerenone may be used in selected patients with type 2 diabetes and albuminuric CKD.
  • Cardiovascular risk reduction is an essential part of management.
  • Progressive disease can lead to Chronic Kidney Disease (CKD) and kidney failure.
  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127. KDIGO .
  • American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). Diabetes Care .
  • Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. Clinical Journal of the American Society of Nephrology .
  • Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-2883. Diabetes Care .
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetic Kidney Disease . National Institutes of Health.
  • National Kidney Foundation. Diabetic Kidney Disease .